Business Context and Reporting Period
Dyadic International, Inc. filed a Form 8-K dated September 25, 2026, reporting Nasdaq listing deficiencies under Item 3.01. The filing does not report operating results for a financial reporting period.
Key Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other current financial metrics. It references the Company’s history of net losses, capital needs, and the potential need for additional funding, but provides no specific amounts.
Material Changes Versus the Prior Comparable Period
- Nasdaq notified the Company that its common stock had remained below the $1.00 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2).
- Nasdaq separately notified the Company that its market value of listed securities had remained below the $35 million minimum for 30 consecutive business days, violating Nasdaq Listing Rule 5550(b)(2).
- Both notices were received on September 25, 2026, and had no immediate effect on the Company’s Nasdaq Capital Market listing.
Guidance, Outlook, Risks, and Contingencies
- The Company has until March 24, 2027, to regain compliance with each requirement.
- For the bid-price deficiency, compliance requires a closing bid price of at least $1.00 for a minimum of 10 consecutive business days, subject to Nasdaq discretion.
- For the market-value deficiency, compliance requires market value of listed securities of at least $35 million for a minimum of 10 consecutive business days, subject to Nasdaq discretion.
- The Company may be eligible for an additional 180-day period to address the bid-price deficiency if it satisfies applicable requirements and provides written notice of its intent to cure, potentially through a reverse stock split. The filing does not state that the Company has authorized or committed to a reverse stock split.
- If deficiencies are not cured, Nasdaq may issue delisting notices. The Company may appeal a delisting determination, but the filing states there can be no assurance that an appeal would succeed.
- Management intends to monitor the common stock’s bid price and market value and evaluate available options to regain compliance.
- Forward-looking risks include the Company’s history of net losses, capital needs, funding availability, regulatory and market acceptance, commercialization and clinical-trial risks, competition, dependence on third parties, intellectual-property risks, changing economic conditions, and continued Nasdaq compliance.
Most Important Facts for Investors to Verify
- Whether the closing bid price reaches at least $1.00 for 10 consecutive business days before March 24, 2027.
- Whether market value of listed securities reaches at least $35 million for 10 consecutive business days before the compliance deadline.
- Whether Nasdaq grants any extension or issues a delisting determination.
- Whether the Company pursues a reverse stock split or another capital-markets action.
- The Company’s current cash balance, liquidity runway, funding requirements, and latest operating results, which are not provided in this filing.